No studies are available on the influence of hormonal contraceptives on the risk of local recurrence or distant metastases for breast cancer in BRCA1/2-pV carriers or carriers with pV in breast and/or ovarian cancer genes other than BRCA1 and BRCA2. The approach should be the same as for women with breast cancer from the general population. This evidence concerns the gene BRCA2 and ovarian carcinoma.